Date
Sponsor content
430 result(s) found, displaying 1 to 10
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for AREXVY Recombinant Respiratory Syncytial Virus pre-fusion F protein vaccine 120 micrograms powder vial and suspension prefilled syringe for injection.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EXDENSUR depemokimab 100 mg solution for injection in pre-filled syringe.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for EXDENSUR depemokimab 100 mg solution for injection in pre-filled pen.
-
Prescription medicine decision summaryExdensur (depemokimab) has been approved as an add-on maintenance treatment for severe asthma in adults and adolescents with eosinophilic airways inflammation, and for the treatment of chronic rhinosinusitis with nasal polyps (CRSwNP) in adults.
-
Jun-2026Prescription medicine evaluationActive ingredient: bepirovirsen sodium.
-
Cancellation by sponsorRequested by GlaxoSmithKline Australia Pty Ltd
-
Australian Public Assessment Report (AusPAR)Blenrep approved for the treatment of relapsed or refractory multiple myeloma in combination with bortezomib and dexamethasone in patients who have received prior therapy and in combination with pomalidomide and dexamethasone.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BLENREP belantamab mafodotin 70 mg powder for injection vial.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for BLENREP belantamab mafodotin 100 mg powder for injection vial.
-
Prescription medicine registrationActive ingredients: Mepolizumab.